ImpediMed Financial Statements From 2010 to 2025
| IPDQF Stock | USD 0.04 0 12.57% |
Check ImpediMed financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ImpediMed's main balance sheet or income statement drivers, such as , as well as many indicators such as . ImpediMed financial statements analysis is a perfect complement when working with ImpediMed Valuation or Volatility modules.
ImpediMed |
ImpediMed Limited Company Profit Margin Analysis
ImpediMed's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current ImpediMed Profit Margin | (1.88) % |
Most of ImpediMed's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ImpediMed Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, ImpediMed Limited has a Profit Margin of -1.8809%. This is 83.22% lower than that of the Healthcare sector and 65.55% lower than that of the Medical Devices industry. The profit margin for all United States stocks is 48.1% higher than that of the company.
ImpediMed Limited Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining ImpediMed's current stock value. Our valuation model uses many indicators to compare ImpediMed value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ImpediMed competition to find correlations between indicators driving ImpediMed's intrinsic value. More Info.ImpediMed Limited is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ImpediMed's earnings, one of the primary drivers of an investment's value.About ImpediMed Financial Statements
ImpediMed stakeholders use historical fundamental indicators, such as ImpediMed's revenue or net income, to determine how well the company is positioned to perform in the future. Although ImpediMed investors may analyze each financial statement separately, they are all interrelated. For example, changes in ImpediMed's assets and liabilities are reflected in the revenues and expenses on ImpediMed's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in ImpediMed Limited. Please read more on our technical analysis and fundamental analysis pages.
ImpediMed Limited, a medical software technology company, develops, manufactures, and sells bioimpedance spectroscopy devices and software services in Australia, North America, and internationally. The company was incorporated in 1999 and is headquartered in Pinkenba, Australia. Impedined operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 73 people.
Currently Active Assets on Macroaxis
| EBR | Centrais Electricas Brasileiras | |
| HE | Hawaiian Electric Industries | |
| VFC | VF Corporation | |
| BVHMF | Vistry Group PLC | |
| S | SentinelOne |
Other Information on Investing in ImpediMed Pink Sheet
ImpediMed financial ratios help investors to determine whether ImpediMed Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ImpediMed with respect to the benefits of owning ImpediMed security.